Masimo Corp Stock Price, News & Analysis

Masimo (NASDAQ: MASI) has released a study demonstrating the benefits of its Patient SafetyNet™ system. Conducted by researchers at Nippon Medical School, the study revealed that the implementation of this technology led to a 61.3% reduction in nursing workload for postoperative respiratory assessments. Nurses reported increased satisfaction with remote monitoring, rising from 78.7% to 89.3% pre- to post-implementation. The findings suggest that continuous monitoring of respiratory rates and oxygen saturation enhances patient safety after general anesthesia.

Spacelabs Healthcare, a division of OSI Systems, has announced an extension of its partnership with Masimo to integrate advanced patient monitoring technologies into Spacelabs multi-parameter monitors. The collaboration will include SET pulse oximetry, NomoLine capnography, and other innovative monitoring solutions.

Both companies aim to enhance patient care by providing deeper insights into patients' physiological conditions, thereby improving outcomes for healthcare providers and patients alike.

Masimo (NASDAQ: MASI) announced a study published in the Journal of Anesthesia & Clinical Research demonstrating the effectiveness of its O3^® Regional Oximetry in monitoring septic shock patients. The research, conducted by Medical College Kolkata, found significant correlations between O3 trends and hemodynamic variables, highlighting its potential as a noninvasive predictor of mortality. The study monitored 40 patients, revealing significant differences in cerebral rSO₂ between survivors and non-survivors over 72 hours. This suggests O3 may provide valuable insights for managing critically ill patients.

Masimo (NASDAQ: MASI) announced a study published in the Journal of Applied Physiology evaluating the Pleth Variability Index (PVi^®) for predicting preload responsiveness in patients receiving nasal high-flow therapy. Conducted by Dr. Marina García-de-Acilu and colleagues, the research involved 20 ICU patients with acute respiratory failure. PVi demonstrated high sensitivity (91.7%) and specificity (87.8%) in identifying preload responders. While the findings suggest potential clinical utility, further validation is needed. The study indicates that PVi may not be universally applicable across all patients treated with high-flow therapy.

Masimo (MASI) reported a strong first quarter 2021, with product revenue soaring by 10.9% to $299.0 million. Excluding certain products, noninvasive technology shipments were 66,000, down from 72,100 year-over-year. GAAP net income decreased to $53.4 million or $0.92 per diluted share, compared to $64.5 million or $1.12 in the previous year. For 2021, the company updated guidance to project total revenue of $1.205 billion, reflecting a 5.4% growth rate, and $3.83 earnings per diluted share.

Masimo (NASDAQ: MASI) has rescheduled its first quarter 2021 financial results release to April 26, 2021, due to executive scheduling changes. The conference call will commence at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by CEO Joe Kiani and CFO Micah Young. Participants can register for the call to receive their unique dial-in details. Masimo is recognized for its advanced medical monitoring technologies aimed at enhancing patient outcomes and reducing healthcare costs, notably with its SET® pulse oximetry technology, which is widely adopted in leading hospitals.

Masimo (NASDAQ: MASI) will release its first quarter 2021 financial results on April 27, 2021, after market close. The conference call for discussing the results, hosted by CEO Joe Kiani and CFO Micah Young, will start at 1:30 p.m. PT (4:30 p.m. ET). Participants can register for the call via a provided link. Masimo is known for its innovative medical monitoring technologies, including the widely used Masimo SET^® pulse oximetry, which is critical in improving patient outcomes and minimizing healthcare costs.

Masimo (NASDAQ: MASI) announced FDA 510(k) clearance for its portable Radius PCG™, a wireless capnograph that offers quick and accurate end-tidal carbon dioxide (EtCO₂) and respiration rate measurements. Designed for seamless integration with the Root^® Patient Monitoring Platform, Radius PCG does not require routine calibration and displays results in 15 seconds. Key features include cable-free operation, automated documentation, enhanced data visibility, and easy Bluetooth connectivity. This device enhances patient monitoring and clinical workflows, especially in emergency settings.

Masimo (NASDAQ: MASI) will present at the 20th Annual Needham Healthcare Conference on April 12, 2021, at 3:45 p.m. Eastern Time. A live webcast will be accessible on the Masimo website, with a replay available post-event. As a leader in medical technology, Masimo develops advanced monitoring solutions to improve patient outcomes and lower care costs. Its industry-standard SET pulse oximetry technology, used in over 100 million patients globally, demonstrates superior performance in critical scenarios. For more details, visit www.masimo.com.